Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    As Oncology Nurses, We Are the Fish
    Oncology nurse pride
    As Oncology Nurses, We Are the Fish
    May 20, 2022
    Patients and the Public Recognize and Thank Dedicated Nurses
    Nurse empowerment
    Patients and the Public Recognize and Thank Dedicated Nurses
    May 06, 2022
    How to Promote and Maintain Cancer Screening as COVID-19 Persists
    Cancer screening
    How to Promote and Maintain Cancer Screening as COVID-19 Persists
    March 18, 2022
    I’m a Match: My Journey From Advanced Practice BMT Nurse to Stem Cell Transplant Donor
    Oncology nurse pride
    I’m a Match: My Journey From Advanced Practice BMT Nurse to Stem Cell Transplant Donor
    February 11, 2022
    Online and Mobile Resources Prepare Oncology Professionals for Care Delivery in All Settings
    Oncology nurse pride
    Online and Mobile Resources Prepare Oncology Professionals for Care Delivery in All Settings
    January 31, 2022
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Cancer research

    Rep. Upton Retires After Leading Historic Cancer Care Legislation
    Cancer healthcare advocacy

    Rep. Upton Retires After Leading Historic Cancer Care Legislation

    U.S. Representative Fred Upton (R-MI) announced that he would not seek another term in the U.S. Congress during his April 2022 House of Representatives floor remarks. In November 2021, Upton and his colleagues introduced the Cures 2.0 Act, which created the Advanced Research Projects Agency for Health (APRA-H) dedicated to finding and researching a cure for cancer.

    May 18, 2022
    E-Cigarettes Increase Risk of Lung and Bladder Cancer More Than Traditional Cigarettes
    Cancer research

    E-Cigarettes Increase Risk of Lung and Bladder Cancer More Than Traditional Cigarettes

    People with a history of e-cigarette use have a higher risk of developing both lung and bladder cancer than never smokers or even users of regular cigarettes, according to study findings researchers reported during the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium.

    May 18, 2022
    Minority Populations Represent Nearly Half of 100,000 Whole Genome Sequences for Researchers Through All of Us
    Genetics & genomics

    Minority Populations Represent Nearly Half of 100,000 Whole Genome Sequences for Researchers Through All of Us

    Among the first set of nearly 100,000 whole genome sequences from participant partners in the National Institutes of Health’s (NIH) All of Us Research Program, “about half come from people who self-identify with a racial or ethnic minority group,” Joshua Denny, MD, MS, All of Us chief executive officer, and Lawrence Tabak, DDS, PhD, NIH acting director, said. “That’s extremely important because, until now, over 90% of participants in large genomic studies were of European descent. This lack of diversity has had huge impacts—deepening health disparities and hindering scientific discovery from fully benefiting everyone.”

    May 16, 2022
    AI Ultrasound Is Nearly 100% Accurate in Detecting Thyroid Cancers
    Cancer research

    AI Ultrasound Is Nearly 100% Accurate in Detecting Thyroid Cancers

    Ultrasound imaging guided with artificial intelligence (AI) noninvasively detects almost all malignant thyroid nodules, researchers reported at the 2022 Multidisciplinary Head and Neck Cancers Symposium. It is also accurate when predicting T stage, extracapsular extension, and presence of a BRAF variant.

    May 11, 2022
    Studies Show Best Practices to Manage CAR T-Cell Therapies’ irAEs and Improve Outcomes
    Immunotherapy

    Studies Show Best Practices to Manage CAR T-Cell Therapies’ irAEs and Improve Outcomes

    Rapid advancements in the science of chimeric antigen receptor (CAR) T-cell therapies present unique challenges and opportunities related to patient care. Nurses are at the forefront of those advancements—contributing to practice guidelines, developing center-specific protocols, publishing outcomes and best practices, and researching the patient experience, outcomes, and supportive interventions.

    May 09, 2022
    NCI Director Steps Down After Successful Tenure
    National Cancer Institute (NCI)

    NCI Director Steps Down After Successful Tenure

    National Cancer Institute (NCI) Director Norman Sharpless, MD, announced his decision to step down as the institute’s director in April 2022, a position he has held since 2017. According to NCI, the institute’s principal deputy director, Douglas R. Lowy, MD, will serve as acting director at the end of the month.

    May 04, 2022
    Research Shows That Vaping Alters Mouth Microbes
    Cancer research

    Research Shows That Vaping Alters Mouth Microbes

    People who use electronic cigarettes have unique microbial communities in their mouths that more closely resembled those of smokers than nonsmokers, which may signal an increased risk of gum disease for those individuals, according to findings from research funded in part by the National Institute of Health’s (NIH’s) National Institute of Dental and Craniofacial Research.

    May 03, 2022
    Targeting Beta2-Spectrin Could Prevent Biggest Contributor to Increasing HCC Rates
    Cancer research

    Targeting Beta2-Spectrin Could Prevent Biggest Contributor to Increasing HCC Rates

    Excessive amounts of a protein called beta2-spectrin may put people at increased risk for nonalcoholic steatohepatitis (NASH), which is the leading cause of hepatocellular carcinoma (HCC), researchers said in a report published in Science Translational Medicine. Developing treatments to lower the protein may help reduce the incidence of both diseases.

    April 27, 2022
    First-Line Combination Immunotherapy Prolongs Survival in BRAF Advanced Melanoma
    Cancer research

    First-Line Combination Immunotherapy Prolongs Survival in BRAF Advanced Melanoma

    Initial treatment with two monoclonal antibodies significantly improves survival for patients with BRAF V600-variant advanced melanoma compared to treatment with two targeted agents, researchers reported during the November 2021 ASCO Plenary Series meeting. The initial findings were so conclusive that the study’s data safety and monitoring board stopped the trial early.

    April 20, 2022
    Breast-Conserving Surgery Leads to Better QOL for Young Breast Cancer Survivors
    Breast cancer

    Breast-Conserving Surgery Leads to Better QOL for Young Breast Cancer Survivors

    Patients younger than 40 who elected to have breast-conserving surgery instead of mastectomy to remove breast cancer reported having better quality of life (QOL) more than five years after diagnosis, according to study findings reported in JAMA Surgery.

    April 13, 2022
    Climate Change Is Contributing to the Cancer Burden, and Nurses Must Take Action
    Oncology nursing roles

    Climate Change Is Contributing to the Cancer Burden, and Nurses Must Take Action

    Climate change affects more than weather patterns or the environment; it also has a substantial impact on human health. Its contribution to the cancer burden includes increased levels of carcinogens, comorbidity factors, cancer incidence, and cancer mortality and reduced access to care.

    April 12, 2022
    E-Cigarettes Are Not an Effective Smoking Cessation Strategy
    Cancer research

    E-Cigarettes Are Not an Effective Smoking Cessation Strategy

    Smokers who try to quit by switching to e-cigarettes do not have more success than those who use other smoking cessation strategies and in fact may be more likely to relapse, researchers found. They reported their study results in Tobacco Control.

    April 06, 2022
    Anxiety and Depression Are Biggest Concerns for Patients With Cancer, Survivors, Caregivers
    Cancer research

    Anxiety and Depression Are Biggest Concerns for Patients With Cancer, Survivors, Caregivers

    As many as 49% of patients with cancer are at risk for clinically significant levels of anxiety and 38% are at risk for clinically significant levels of depression, according to data collected through the Cancer Support Community’s (CSC’s) cancer experience registry. Additionally, nearly half of caregivers have anxiety levels that are substantially higher than the national average and one-third face substantially higher fatigue and depression levels. Nationally, the rates for levels of anxiety and depression are 19.1% of U.S. adults aged 18 and older and 8.4% of U.S. adults aged 18 and older, respectively.

    March 29, 2022
    Fiber—but Not Probiotics—Boosts Immunotherapy Response for Melanoma
    Immunotherapy

    Fiber—but Not Probiotics—Boosts Immunotherapy Response for Melanoma

    Patients with melanoma who consume a high-fiber diet during treatment with immune checkpoint inhibitors (ICIs) or anti-PD-1 therapy experience longer progression-free survival than those who don’t, researchers reported in Science. And probiotic supplementation, often considered a healthy behavior, reduces immunotherapy response.

    March 23, 2022
    NCI Office of Cancer Survivorship Funded More Than $10
    National Cancer Institute (NCI)

    NCI Office of Cancer Survivorship Funded More Than $100 Million for Survivorship Research in 2020

    More than 150 Office of Cancer Survivorship grants totaling nearly $112 million funded research on cancer survivorship in 2020, including “resources for implementation of the STAR Act and additional resources provided through legislation such as the 21st Century Cures Act, which authorized funding for the Cancer Moonshot,” according to the office’s 25th anniversary report.

    March 22, 2022
    Even Insured Patients With Advanced Cancer Experience Financial Toxicity
    Patient financial advocacy

    Even Insured Patients With Advanced Cancer Experience Financial Toxicity

    As many as 71% of patients with advanced cancer—most of whom have healthcare insurance—experience major financial hardship because of their disease, according to study findings published in the Journal of the National Cancer Institute.

    March 16, 2022
    Rural Populations’ Fatalistic Perceptions About Cancer May Contribute to Cancer Disparities
    Cancer research

    Rural Populations’ Fatalistic Perceptions About Cancer May Contribute to Cancer Disparities

    Compared to people living in urban areas, on a nationwide U.S. survey, rural populations were more likely to report believing that cancer is unpreventable and always fatal. Researchers reported the survey findings and analysis in Cancer Epidemiology, Biomarkers, and Prevention.

    March 09, 2022
    Nursing Considerations for ICI-Related Myocarditis
    Cancer research

    Nursing Considerations for ICI-Related Myocarditis

    Before immunotherapies like immune checkpoint inhibitors (ICIs) became a cancer treatment option, myocarditis typically developed in the presence of infections, drug allergies, or autoimmune diseases. Activating the immune system with ICIs can also trigger autoimmune-like adverse events such as myocarditis, and although its incidence in patients with cancer is low, mortality is high.

    March 08, 2022
    Biden Names Interim Leaders to Office of Science and Technology Policy
    Cancer healthcare advocacy

    Biden Names Interim Leaders to Office of Science and Technology Policy

    Building support for the Cancer Moonshot reignition, President Joe Biden appointed temporary leaders to streamline the White House Office of Science and Technology Policy’s (OSTP’s) agenda of creating the Advanced Research Projects Agency for Health. Alondra Nelson, PhD, will serve as OSTP director and Francis Collins, MD, PhD, as science advisor to the president and co-chair of the President’s Council of Advisors on Science and Technology until permanent leaders are in place. Biden made the appointments in February 2022 after Eric Lander, his science advisor who also served as OSTP director, announced his resignation from the role.

    March 07, 2022
    Specialized Risk Calculator May Reduce Disparities for Black Patients With Breast Cancer
    Cancer health disparities

    Specialized Risk Calculator May Reduce Disparities for Black Patients With Breast Cancer

    A new risk model tailored for Black patients predicts their risk of developing breast cancer as accurately as current models for White patients, researchers reported in the Journal of Clinical Oncology. Because Black patients are more likely to be younger at diagnosis, present with aggressive or advanced cancer, and die from the disease than other racial and ethnic groups, using the new model to personalize prevention and screening recommendations may reduce those disparities.

    March 02, 2022
    $9 Billion in COVID-19 Relief Funds Support Healthcare Institutions
    COVID-19

    $9 Billion in COVID-19 Relief Funds Support Healthcare Institutions

    Provider Relief Fund Phase 4 payments distributed approximately $9 billion to more than 69,000 healthcare institutions that have experienced revenue losses and expenses related to the COVID-19 pandemic, the U.S. Department of Health and Human Services (HHS) announced in December 2021.

    February 25, 2022
    Immune Checkpoint Inhibitors May Increase Risk of Serious Infection
    Cancer research

    Immune Checkpoint Inhibitors May Increase Risk of Serious Infection

    Nearly a quarter of patients receiving a variety of drugs classified as immune checkpoint inhibitors develop infections during treatment and 15% are considered severe, researcher reported in study findings published in Cancer Medicine.

    February 23, 2022
    Immunotherapy After Surgery May Prevent Early-Stage Melanoma Recurrence
    Cancer research

    Immunotherapy After Surgery May Prevent Early-Stage Melanoma Recurrence

    Completing up to a year of pembrolizumab immunotherapy after surgical resection of stage IIB or IIC melanoma decreases patients’ risk for disease recurrence or death by 35%, according to study findings presented at the European Society for Medical Oncology 2021 annual meeting. The new findings led the U.S. Food and Drug Administration to expand its approval of pembrolizumab to use as adjuvant therapy in both adults and children aged 12 and older with early-stage melanoma.

    February 16, 2022
    Geriatric Assessments Reduce Side Effect Incidence in Older Adults With Cancer
    Cancer research

    Geriatric Assessments Reduce Side Effect Incidence in Older Adults With Cancer

    Regularly conducting geriatric assessments in older patients and using the information to guide their care reduces their risk of side effects by nearly 30%, researchers reported in study findings published in Lancet.

    February 09, 2022
    Nursing Considerations for Isatuximab Combination Therapy
    Combination therapy

    Nursing Considerations for Isatuximab Combination Therapy

    Clinicians often use combination cancer therapies to overcome treatment resistance, and one of the newest options for certain patients with multiple myeloma is isatuximab, a monoclonal antibody (mAb). Approved for use in combination with pomalidomide plus dexamethasone to treat adults with relapsed or refractory multiple myeloma who have received at least two prior therapies, isatuximab prolonged progression-free survival by nearly six months and produced an overall response rate of more than 60% in the drug’s clinical trials.

    February 08, 2022
    President Biden Reignites Cancer Moonshot Initiative
    Cancer moonshot

    President Biden Reignites Cancer Moonshot Initiative

    The explosion of immunotherapy in your practice? You can thank the Cancer Moonshot. New discoveries in oncodrivers for childhood cancers? Thank the Moonshot again. You can also thank it for better cancer prevention and screening strategies, attention to patient-centered care, and interprofessional collaboration among oncology scientists and clinicians.

    February 07, 2022
    Combination CDK4/6 and Fulvestrant Has Survival Benefits in Late-Stage Breast Cancer
    Cancer research

    Combination CDK4/6 and Fulvestrant Has Survival Benefits in Late-Stage Breast Cancer

    Combining a CDK4/6 inhibitor and fulvestrant improves overall survival consistently among patients with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer, according to a U.S. Food and Drug Administration (FDA) analysis. The agency reported the findings in Lancet Oncology.

    February 02, 2022
    Never Smokers With Lung Cancer May Have One of Three Molecular Subtypes
    Lung Cancer

    Never Smokers With Lung Cancer May Have One of Three Molecular Subtypes

    Most lung cancers in patients who have no smoking history are the result of natural genetic variants in the body that can be classified into one of three molecular subtypes, researchers reported in study finding published in Nature Genetics.

    January 26, 2022
    President and First Lady Biden Recognize National Cancer Act’s 50th Anniversary
    National Cancer Institute (NCI)

    President and First Lady Biden Recognize National Cancer Act’s 50th Anniversary

    On December 23, 1971, the National Cancer Act was signed into law by Former President Richard Nixon, granting authority to the National Cancer Institute (NCI) director to develop a national cancer program. In December 2021, First Lady Jill Biden celebrated the legislation’s 50th anniversary in an NCI video, in which she recognized the importance of the act, cancer advocacy, and the disease’s personal impact on her family.

    January 25, 2022
    Cancer Cells’ Aneuploidy May Be Why They Resist Treatment
    Cancer research

    Cancer Cells’ Aneuploidy May Be Why They Resist Treatment

    The extra or missing chromosomes—also called aneuploidy—in 90% of cancer cells may be a factor in treatment resistance, a new study shows. Researchers reported the findings in Developmental Cell.

    January 19, 2022
    Fructose Fuels Colorectal Cancer Growth, Study Shows
    Cancer research

    Fructose Fuels Colorectal Cancer Growth, Study Shows

    Excess consumption of fructose in additives like table sugar or high-fructose corn syrup (HFCS) not only contributes to obesity, but it may increase colorectal cancer (CRC) cell survival, leading to larger tumors and increased symptom burden in patients at higher risk, researchers showed in study results published in Nature. However, blocking the body’s uptake of the sweetener may be a key to controlling the disease.

    January 12, 2022
    NIH Diversity Research Program Gets New Chief Medical and Scientific Officer
    Access to cancer care

    NIH Diversity Research Program Gets New Chief Medical and Scientific Officer

    A pioneer and internationally recognized expert in translational genomics and precision medicine will guide the scientific vision, strategy, and data collection for the next phase of the National Institutes of Health’s (NIH’s) All of Us Research Program, the agency announced. In November 2021, NIH appointed Geoffrey Ginsburg, MD, PhD, to serve as the program’s chief medical and scientific officer.

    January 10, 2022
    Education, Insurance, and Marital Status Linked to Disparities in Survivorship Care Plans
    Survivorship care plans

    Education, Insurance, and Marital Status Linked to Disparities in Survivorship Care Plans

    Older cancer survivors who have lower levels of education, are uninsured, or are widowed, divorced, or separated are less likely to receive survivorship care plans (SCPs), researchers found. They reported the results of their study in Supportive Care in Cancer.

    January 05, 2022
    Liver Cancer Diagnoses See Geographic, Racial, Income Disparities
    Cancer health disparities

    Liver Cancer Diagnoses See Geographic, Racial, Income Disparities

    The urban-rural disparity in hepatocellular cancer (HCC) diagnoses is widening, researchers said, particularly in certain racial, income, and age groups. The authors reported their study results in Clinical Gastroenterology and Hepatology.

    December 29, 2021
    Telehealth Has Value During Radiotherapy, Patients Say
    Patient resources

    Telehealth Has Value During Radiotherapy, Patients Say

    More than 90% of patients report that telehealth consultations during radiotherapy treatment are high quality and may be even better for understanding information from their healthcare team than in-person visits, researchers reported in the Journal of the National Comprehensive Cancer Network.

    December 22, 2021
    Traits That Make You  a Great Nurse Also Lead to Success as a Clinical Trials PI
    Oncology clinical trials

    Traits That Make You a Great Nurse Also Lead to Success as a Clinical Trials PI

    Clinical trials are led by a principal investigator (PI) with a research team that may include physicians, nurses, social workers, and other healthcare professionals. PIs can represent a variety of disciplines, and nurse scientists often hold that role.

    December 14, 2021
    Use ClinicalTrials.gov to Find the Right Cancer Research Studies for Your Patients
    Oncology clinical trials

    Use ClinicalTrials.gov to Find the Right Cancer Research Studies for Your Patients

    Among the many online resources for identifying cancer clinical trials, including the National Cancer Institute (NCI), NCI-designated cancer centers or academic cancer centers, and drug and biotechnology companies, ClinicalTrials.gov may be the most comprehensive as a one-stop shop for patients and providers to find publicly and privately supported trials for patients.

    December 09, 2021
    First KRAS-Targeted Therapy Receives FDA Approval for Lung Cancer
    Cancer research

    First KRAS-Targeted Therapy Receives FDA Approval for Lung Cancer

    Sotorasib offers a durable clinical benefit without new safety signals in patients with previously treated KRAS p.G12C-variant non-small cell lung cancer, according to the results of a clinical trial that led to the therapy’s U.S. Food and Drug Administration (FDA) approval. The researchers reported the findings in the New England Journal of Medicine.

    November 24, 2021
    New NIH Program Aims to Increase Gene Therapies for Rare Diseases
    Cancer research

    New NIH Program Aims to Increase Gene Therapies for Rare Diseases

    To accelerate the development of gene therapies for the 30 million Americans who have been diagnosed with a rare disease, in October 2021 the National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), 10 pharmaceutical companies, and five nonprofit organizations announced the creation of the Bespoke Gene Therapy Consortium (BGTC). The consortium is optimizing and streamlining the gene therapy development process to help fill the unmet medical needs of people with rare diseases.

    November 18, 2021
    Mid-Century Antibiotic May Offer Options After PARP Inhibitor Resistance
    Cancer research

    Mid-Century Antibiotic May Offer Options After PARP Inhibitor Resistance

    Novobiocin, an antibiotic discovered during the 1950s, may be a potential second-line therapy for patients whose tumors have become resistant to poly (ADP-ribose) polymerase (PARP) inhibitors, researchers reported in Nature Cancer. The finding may open up new options for patients with BRCA-variant disease such as breast, ovarian, pancreatic, and prostate cancer.

    November 17, 2021
    New Radiopharmaceutical Improves Survival in Advanced Prostate Cancer
    Prostate cancer

    New Radiopharmaceutical Improves Survival in Advanced Prostate Cancer

    Among patients with metastatic, castration-resistant prostate cancer, treatment with the experimental 177Lu-PSMA-617 radiopharmaceutical, along with other standard treatments, improved survival by four months over treatment with standard therapies alone, researchers reported in the New England Journal of Medicine. The therapy targets the PMSA protein and may one day be an option when other treatments have failed.

    November 10, 2021
    New U.S. Agency Will Propel Healthcare Advancements Directly Into Practice
    Cancer healthcare advocacy

    New U.S. Agency Will Propel Healthcare Advancements Directly Into Practice

    Biomedical research is what transforms medicine. Oncology nurses see the evidence of that daily, from discoveries like immunotherapy that have revolutionized cancer treatment to novel nursing approaches to managing symptoms and adverse events. And thanks to the studies that brought a COVID-19 coronavirus vaccine to market in record-breaking time, the world understands research like never before, too.

    October 21, 2021
    NIH Provides $185 Million to Advance Understanding of Human Genome Functions
    Cancer research

    NIH Provides $185 Million to Advance Understanding of Human Genome Functions

    To drive the advancement of our understanding of the human genome, the National Institute of Health (NIH) is providing $185 million in funding over the next five years, the agency announced in September 2021.

    October 15, 2021
    NCI Proposes Budget for Fiscal Year 2023
    National Cancer Institute (NCI)

    NCI Proposes Budget for Fiscal Year 2023

    Driving “cancer research that spans the continuum from basic science to survivorship” and taking advantage of the “incredible opportunity to greatly reduce the impact of cancer on people’s lives and end cancer as we know it” takes an investment, the National Cancer Institute (NCI) acknowledged in its proposed budget for the 2023 fiscal year. However, fully funding “cutting-edge research, infrastructure, and training needed to harness these opportunities allows researchers better understand how to prevent and treat cancer.”

    September 29, 2021
    State Cancer Registries Studies Find Nearly All Patients With Cancer Recovered From COVID-19
    COVID-19

    State Cancer Registries Studies Find Nearly All Patients With Cancer Recovered From COVID-19

    Many patients are delaying their recommended cancer screenings because of fear of death from COVID-19 coronavirus infection, according to the Centers for Disease Control and Prevention (CDC). However, those fears may not align with real-world outcomes, the agency said, when it reported July 2021 study findings from Arkansas and North Carolina.

    September 28, 2021
    This Is Why Red Meat Increases Colorectal Cancer Risk
    Cancer research

    This Is Why Red Meat Increases Colorectal Cancer Risk

    Frequent red and processed meat consumption leaves a specific pattern of DNA damage in colorectal cells that contributes to the formation of tumors, researchers reported in study findings published in Cancer Discovery.

    September 15, 2021
    Patient-Advocacy-Provider Partnerships and Networks Support Rare Cancer Research
    Cancer research

    Patient-Advocacy-Provider Partnerships and Networks Support Rare Cancer Research

    My area of research focus is adults with primary central nervous system (CNS) tumors, which represent less than 2% of all diagnosed cancers. Because of the cancers’ rarity, access to diagnosed patients for research initiatives is limited. My team’s program, NCI-CONNECT, a part of the Rare Tumor Patient Engagement Network supported by the Cancer Moonshot, is advancing our understanding of adults with rare CNS cancers by establishing patient-advocacy-provider partnerships and networks to improve care and treatment approaches.

    September 14, 2021
    A Body of Evidence Helps Nurses Manage CAR T-Cell Therapy Toxicities
    Cancer research

    A Body of Evidence Helps Nurses Manage CAR T-Cell Therapy Toxicities

    When chimeric antigen receptor (CAR) T-cell therapies were first approved for cancer in 2017, nurses didn’t have years of clinical practice experience with the treatment to understand its full scope of nursing implications yet. Now that nearly five years have passed—and new CAR T-cell therapies have been approved, bringing the total number of treatments to five as well—oncology nurses and nurse scientists have built a robust knowledge base.

    September 14, 2021
    ONS Bridge

    Follow the Evidence When Using Scalp Cooling for Cancer Alopecia

    Scalp cooling, also known as cryotherapy, may reduce the risk of chemotherapy-induced alopecia (CIA) in patients with cancer, but how do you know if the therapy is right for your patients? According to speakers at an ONS BridgeTM virtual conference session on September 9, 2021, start with the evidence.

    September 09, 2021
    Rare Cancer Advocacy Programs Help Patients Discover Resources and Make Connections
    Cancer research

    Rare Cancer Advocacy Programs Help Patients Discover Resources and Make Connections

    A cancer diagnosis can be difficult for any patient to receive, but a rare cancer diagnosis can put additional stress on a patient and their family. They may feel isolated and struggle to find accurate information on their diagnosis, which may be minimal because of limited funding and research. Rare cancer advocacy groups and programs offer critical patient support and empowerment, raise awareness, and initiate research for treatments.

    September 07, 2021
    • Current page 1
    • Page 2
    • Page 3
    • Page 4
    • Page 5
    • Next page
    • Last page Last »
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    • Cancer research
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2022 Oncology Nursing Society
     
    Back to Top ▲